MA-BRIGHTCOVE-INC
14.7.2020 15:02:53 CEST | Business Wire | Press release
Brightcove Inc. (NASDAQ: BCOV), the world’s leading video technology platform, today announced the expansion of the Brightcove Global Partner Program , designed to further extend the power of video to reach global audiences quickly and easily. With a broad portfolio of partners specifically focused on media and enterprise organizations, the Brightcove Global Partner Program broadens the reach of Brightcove’s leading video technology solutions, which help fuel innovation and drive transformative business strategies with video.
Video is now a requirement to be a successful business. Brightcove’s Global Partner Program makes video technology readily available to organizations globally and enables them to implement it quickly through the channels that align best with their business models. By building a community of world-class partners, Brightcove is further democratizing the consumption of video, enabling companies around the world to bring their stories to viewers everywhere.
The newly-expanded program accommodates forward-thinking companies committed to ensuring the best experience for customers and end-users. The program consists of three types of partners:
- Referral Partners: Partners that refer their clients to Brightcove directly for a full video solution.
- Solution Partners: Systems integrators and resellers that build full video management solutions for their enterprise and media clients.
- Master License Partners: Partners that deliver Brightcove’s video technology and solutions as a managed service provider to clients of all sizes that demand the quality, choice, and support that Brightcove provides.
The Master License Partner program puts the full Brightcove platform within reach for all size clients. This new program allows Master License Partners to build upon their expertise, keeping them front and center to their clients, and now they are able to deliver world-class Brightcove video to their customers. Regardless of size, content type, and location, partners and clients alike are able to leverage leading video technology backed by Brightcove.
“As we continue to help enterprises broadcast their video content online, we want to ensure we’re offering them the most robust and premier video solutions available on the market,” said Blaise Kremer, Co-Founder, NovaStream. “Brightcove’s solutions allow the organizations we work with to enhance the delivery of their video content to their audiences, resulting in broader reach and exceptional viewing experiences. We are excited to be a part of Brightcove’s Partner Program, and look forward to helping more companies reap the benefits of video.”
"We are thrilled to be a part of Brightcove’s Global Partner Network and to help our customers stay at the forefront of the video revolution,” said Nuthapong Temsiripong, CEO, Digital Solution International Co., Ltd. “We have a long-standing relationship with Brightcove and have worked closely together to help media companies reduce their video streaming costs and increase revenue. As we move into the new partner program with additional enhancements and resources, we are excited to see our mutual customers continue to succeed with video.”
“Brightcove is committed to providing a strong global partner and channel ecosystem to support the demanding video needs for our customers,” said Lynn D. Tinney, Vice President, Global Partners at Brightcove. “Customers are our number one priority and we have enhanced our global partner program to enable them to deliver exceptional video experiences and exceed their audience’s expectations. Our partners offer services and solutions that are at the forefront of the digital transformation and with Brightcove as the core technology powering this network, we enable organizations that are serious about video to deliver secure and reliable content to viewers around the world.”
For more information on the Brightcove Global Partner Program, visit: https://www.brightcove.com/en/become-a-partner
About Brightcove Inc. (NASDAQ: BCOV)
We are the people behind the world’s leading video technology platform. With our award-winning technology and services, we help organizations in more than 70 countries meet business challenges and create strategic opportunities by inspiring, entertaining, and engaging their audiences through video.
Since Brightcove was established in 2004, we have consistently pushed boundaries to create a platform for people who are serious about video: one that is robust, scalable, and intuitive. Benefiting from a global infrastructure, unrivalled customer support, an extensive partner ecosystem, and relentless investment in R&D, Brightcove video sets the standard for professional grade video management, distribution, and monetization. To learn more, visit www.brightcove.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005607/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom